Acelyrin (SLRN) Projected to Post Quarterly Earnings on Thursday

Acelyrin (NASDAQ:SLRN) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.84) per share for the quarter.

Acelyrin (NASDAQ:SLRN) last released its earnings results on Wednesday, March 19th. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.07. On average, analysts expect Acelyrin to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acelyrin Price Performance

NASDAQ SLRN opened at $2.79 on Thursday. Acelyrin has a 12 month low of $1.85 and a 12 month high of $8.59. The company has a 50-day moving average of $2.26 and a 200-day moving average of $3.84. The company has a market cap of $279.91 million, a P/E ratio of -1.13 and a beta of 1.25.

Analyst Ratings Changes

SLRN has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their target price on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. Citigroup reduced their target price on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Finally, HC Wainwright reduced their price objective on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Acelyrin presently has an average rating of “Hold” and an average price target of $9.60.

Insiders Place Their Bets

In other news, CEO Mina Kim sold 17,986 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. This trade represents a 2.61 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 13.60% of the stock is owned by corporate insiders.

About Acelyrin

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.